Damora Therapeutics, Inc. (DMRA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DMRA SEC filings page.
This page shows Damora Therapeutics, Inc. (DMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity financing and noncash accounting effects dominate the reported business profile, while operating activity remains difficult to assess without revenue.
In FY2025, the net loss reached-$209.8M , yet operating cash flow was only-$6.7M ; paired with$266.8M of financing cash flow, this indicates the period’s reported loss did not translate into equivalent operating cash use and that balance-sheet expansion was funding-led rather than operations-led.
The FY2025 loss step-change is not explained by the listed operating expenses: R&D fell to
The company’s financing structure remained equity-funded rather than debt-led: total equity rose to
Financial Health Signals
Damora Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Damora Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Damora Therapeutics, Inc. reported a net loss of $209.8M while operations used $6.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Damora Therapeutics, Inc. reported an operating loss of $210.9M against $1.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Damora Therapeutics, Inc.'s EBITDA was -$35.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 924.5% from the same quarter a year earlier. Against the prior quarter it is down 13.6%.
Damora Therapeutics, Inc. reported -$31.2M in net income in Q2 2026. This represents a decrease of 807.0% from the same quarter a year earlier. Against the prior quarter it is down 12.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
Damora Therapeutics, Inc. held $540.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Damora Therapeutics, Inc.'s ROE was -6.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 25.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Damora Therapeutics, Inc. invested $25.5M in research and development in Q2 2026. This represents an increase of 1643.3% from the same quarter a year earlier. Against the prior quarter it is up 7.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
DMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $25.5M+1643.3% | $23.8M+3406.9% | N/A | $1.4M+29.6% | $1.5M-20.1% | $678K-72.5% | N/A | $1.1M-57.2% |
| SG&A Expenses | $9.5M+383.3% | $7.0M+266.2% | N/A | $1.7M-36.7% | $2.0M-29.5% | $1.9M-41.4% | N/A | $2.7M-16.9% |
| Operating Income | -$35.0M-922.9% | -$30.8M-1085.5% | N/A | -$3.2M+17.8% | -$3.4M+38.7% | -$2.6M+54.7% | N/A | -$3.8M+55.3% |
| EBITDA | -$35.0M-924.5% | -$30.8M-1087.6% | N/A | -$3.1M+17.8% | -$3.4M+38.7% | -$2.6M+54.8% | N/A | -$3.8M+54.2% |
| Interest Expense | $4.1M+8018.0% | $3.1M+4048.6% | N/A | $42K-71.2% | $50K-76.5% | $74K-71.2% | N/A | $146K-69.1% |
| Income Tax | $255K+6275.0% | $42K+2000.0% | N/A | $0-100.0% | $4K-90.5% | $2K | N/A | $7K |
| Net Income | -$31.2M-807.0% | -$27.8M-996.8% | N/A | -$3.1M+19.3% | -$3.4M+35.6% | -$2.5M+53.8% | N/A | -$3.9M+52.3% |
| EPS (Basic) | -$0.39+85.0% | -$0.62+67.7% | $10.86+307.6% | -$2.36+30.4% | -$2.60+47.2% | -$1.92+62.0% | -$5.23+11.2% | -$3.39+54.8% |
| EPS (Diluted) | -$0.39 | -$0.62 | $10.86 | -$2.36+30.4% | -$2.60 | -$1.92 | -$5.23 | -$3.39 |
| Diluted Shares (Avg) | 61M | 34M | N/A | 1M+15.9% | 1M | 1M | N/A | 1M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
DMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $543.6M+3870.8% | $535.4M+3384.8% | $260.5M+1420.7% | $10.7M-54.1% | $13.7M-49.8% | $15.4M-52.7% | $17.1M-55.2% | $23.4M-53.3% |
| Current Assets | $543.6M+4072.8% | $535.4M+3487.8% | $260.4M+1446.5% | $9.8M-53.8% | $13.0M-48.2% | $14.9M-51.1% | $16.8M-54.2% | $21.2M-55.0% |
| Cash & Equivalents | $540.5M+5193.5% | $532.9M+4363.5% | $257.6M+1717.5% | $7.6M-61.3% | $10.2M-55.3% | $11.9M-43.4% | $14.2M-34.0% | $19.7M-14.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $27.6M+907.2% | $23.8M+1339.6% | $20.1M+1448.6% | $2.7M+11.8% | $2.7M-26.2% | $1.7M-61.6% | $1.3M-77.9% | $2.4M-80.7% |
| Current Liabilities | $27.6M+947.9% | $23.8M+1435.3% | $20.1M+1576.4% | $2.6M+7.5% | $2.6M-29.1% | $1.6M-64.1% | $1.2M-79.5% | $2.4M-80.6% |
| Non-Current Liabilities | $27K-75.2% | $27K-74.3% | $81K-22.1% | $106K | $109K | $105K | $104K+57.6% | $0-100.0% |
| Total Equity | $516.1M+4611.6% | $511.6M+3631.9% | $240.4M+1418.4% | $8.0M-61.8% | $11.0M-53.6% | $13.7M-51.3% | $15.8M-51.0% | $20.9M-44.0% |
| Retained Earnings | -$546.3M-92.7% | -$515.1M-83.9% | -$487.4M-75.6% | -$286.6M-5.9% | -$283.5M-6.2% | -$280.1M-7.1% | -$277.5M-8.4% | -$270.8M-8.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
DMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.9M-877.5% | -$20.6M-744.5% | $566K+111.5% | -$2.6M+28.3% | -$2.2M+45.4% | -$2.4M+58.9% | -$4.9M+57.0% | -$3.7M+56.8% |
| Depreciation & Amortization | $6K0.0% | $5K0.0% | $6K+20.0% | $6K0.0% | $6K+20.0% | $5K0.0% | $5K-78.3% | $6K-97.2% |
| Stock-Based Compensation | $10.7M+6113.4% | $3.1M+1650.8% | N/A | $164K-75.9% | $172K-80.7% | $179K-86.8% | N/A | $681K-53.5% |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0-100.0% |
| Financing Cash Flow | $29.5M | $295.9M | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
DMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -6.0%+25.3pp | -5.4%+13.1pp | N/A | -39.1%-20.6pp | -31.4%-8.8pp | -18.5%+1.0pp | N/A | -18.6%+3.2pp |
| Return on Assets | -5.7%+19.4pp | -5.2%+11.3pp | N/A | -29.2%-12.6pp | -25.1%-5.5pp | -16.5%+0.4pp | N/A | -16.6%-0.4pp |
| Current Ratio | 19.73+14.8x | 22.48+12.9x | 12.98-1.1x | 3.73-4.9x | 4.96-1.8x | 9.62+2.5x | 14.07+7.8x | 8.68+4.9x |
| Debt-to-Equity | 0.05-0.2x | 0.05-0.1x | 0.080.0x | 0.34+0.2x | 0.25+0.1x | 0.120.0x | 0.08-0.1x | 0.12-0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Where Damora Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Damora Therapeutics, Inc. profitable?
No, Damora Therapeutics, Inc. (DMRA) reported a net income of -$209.8M in fiscal year 2025.
What is Damora Therapeutics, Inc.'s EBITDA?
Damora Therapeutics, Inc. (DMRA) had EBITDA of -$210.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Damora Therapeutics, Inc.'s return on equity (ROE)?
Damora Therapeutics, Inc. (DMRA) has a return on equity of -87.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Damora Therapeutics, Inc.'s operating cash flow?
Damora Therapeutics, Inc. (DMRA) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Damora Therapeutics, Inc.'s total assets?
Damora Therapeutics, Inc. (DMRA) had $260.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Damora Therapeutics, Inc. spend on research and development?
Damora Therapeutics, Inc. (DMRA) invested $26.9M in research and development during fiscal year 2025.
What is Damora Therapeutics, Inc.'s current ratio?
Damora Therapeutics, Inc. (DMRA) had a current ratio of 12.98 as of fiscal year 2025, which is generally considered healthy.
What is Damora Therapeutics, Inc.'s debt-to-equity ratio?
Damora Therapeutics, Inc. (DMRA) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Damora Therapeutics, Inc.'s return on assets (ROA)?
Damora Therapeutics, Inc. (DMRA) had a return on assets of -80.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Damora Therapeutics, Inc.'s P/E ratio?
Damora Therapeutics, Inc. (DMRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.3B as of Sep 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Damora Therapeutics, Inc.'s price-to-sales ratio?
Damora Therapeutics, Inc. (DMRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.3B as of Sep 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Damora Therapeutics, Inc.'s Piotroski F-Score?
Damora Therapeutics, Inc. (DMRA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Damora Therapeutics, Inc.'s earnings high quality?
Damora Therapeutics, Inc. (DMRA) reported a net loss of $209.8M while operations used $6.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Damora Therapeutics, Inc. cover its interest payments?
Damora Therapeutics, Inc. (DMRA) reported an operating loss of $210.9M against $1.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.